Pharmaceuticals · Nasdaq Copenhagen
Novo Nordisk
Dados de preço: widget da TradingView abaixo
Novo Nordisk (NOVO-B) — Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
Why people search for it: Searched as Europe’s obesity/diabetes pharma leader — Ozempic/Wegovy keep the ticker in global headlines.
A carregar gráfico…
Open NOVO-B chart in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
A carregar gráfico…
📐 Análise técnica
A carregar gráfico…
Resumo de indicadores da TradingView (médias móveis, osciladores). Um sinal mecânico, não um conselho.
Open technicals in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
📊 Fundamentais
A carregar gráfico…
🏢 Perfil da empresa
A carregar gráfico…
📰 Últimas notícias de NOVO-B
A carregar gráfico…
🧩 O que é
Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
⚡ Porque é interessante
It became one of Europe’s most valuable companies as demand for weight-loss and diabetes drugs surged worldwide, keeping NOVO-B in constant search interest.
⚠️ Principais riscos
Valuation prices in rapid growth; competition in GLP-1, supply constraints, pricing pressure and any safety headlines can move the stock sharply. Currency (DKK/EUR) matters for international investors.
👀 O que acompanhar
GLP-1 sales, manufacturing capacity, rival trial data and US pricing/reimbursement news.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions. Contains a TradingView affiliate link.
❓ Novo Nordisk: perguntas frequentes
O que é Novo Nordisk (NOVO-B)?
Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
Porque é que as pessoas acompanham Novo Nordisk?
It became one of Europe’s most valuable companies as demand for weight-loss and diabetes drugs surged worldwide, keeping NOVO-B in constant search interest.
Why do people search for Novo Nordisk?
Searched as Europe’s obesity/diabetes pharma leader — Ozempic/Wegovy keep the ticker in global headlines.
Quais são os principais riscos de Novo Nordisk?
Valuation prices in rapid growth; competition in GLP-1, supply constraints, pricing pressure and any safety headlines can move the stock sharply. Currency (DKK/EUR) matters for international investors.
O que devo acompanhar em Novo Nordisk?
GLP-1 sales, manufacturing capacity, rival trial data and US pricing/reimbursement news.
Novo Nordisk é um bom investimento?
A Hodlia não presta aconselhamento de investimento. Se Novo Nordisk é adequado para si depende dos seus objetivos, do seu horizonte temporal e de quantas perdas consegue suportar. Ações individuais podem cair muito mesmo com os mercados calmos. Leia os riscos acima, compare com uma alternativa diversificada e considere aconselhamento independente.